09:16 AM EDT, 04/18/2024 (MT Newswires) -- Viatris ( VTRS ) and Theramex's undertakings related to Viatris' ( VTRS ) proposed divestment of the UK rights to its Femoston and Duphaston products to Theramex are being considered by Britain's Competition and Markets Authority, according to the regulator's website on Thursday.

"The CMA considers that there are reasonable grounds for believing that the undertakings offered by the parties, or a modified version of them, might be accepted by the CMA under the Enterprise Act," the CMA said. The competition watchdog did not provide further details on the companies' undertakings.

The regulator has until June 17 to decide whether to accept the undertakings but may extend the timeframe to Aug. 12, the London Stock Exchange said in a separate statement.